Price movement over the last 24 hours
Amazon.com Inc vs ClearPoint Neuro Inc — how do they compare? Amazon.com Inc trades at $244.61 (market cap $2.64T), while ClearPoint Neuro Inc trades at $17.19 (market cap $524.82M). The key difference: Amazon.com Inc is far larger — about 5030.3× ClearPoint Neuro Inc's market cap, and Amazon.com Inc is trading nearer its 52-week high, ClearPoint Neuro Inc nearer its low. Which is the better fit depends on your goals.
| AMZN | CLPT | |
|---|---|---|
Market Cap | $2.64T | $524.82M |
Volume | 3,931,282 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $274.95 | $29.60 |
52-Week Low | $198.79 | $8.66 |
Enterprise Value | $2.71T | $552.81M |
Signals from Pluang's Aura AI — not financial advice
Amazon (AMZN) trades at $245.34, down 0.69% on the day, with a bullish technical outlook supported by moving averages. The company reported strong Q1 2026 earnings, beating expectations with EPS of $2.78, and shows robust revenue growth, reaching $716.92B in 2025. Operating cash flow remains strong at $139.51B, though heavy investing activities result in modest net cash flow. Analyst sentiment is overwhelmingly positive, with 88.3% recommending Buy and a consensus price target of $320.75.
The outlook for Amazon is favorable, driven by AI advancements in AWS and expanding market penetration. Key risks include intense competition in retail and cloud sectors, high capital expenditures, and macroeconomic pressures. Investors should weigh the strong growth trajectory against these risks, with the stock offering significant upside based on analyst targets.
ClearPoint Neuro (CLPT) trades at $17.50, down 2.13% on the day, with a bullish technical signal from moving averages despite recent earnings misses. The company reported record Q1 2026 revenue of $41M with 43% growth but continues to post significant net losses, reflected in a negative net income margin of -71.57%. Recent FDA clearance for its Velocity Alpha surgical drill and a new partnership in South Korea highlight ongoing business development efforts.
The investment case hinges on CLPT's positioning in the gene therapy enabling space, with 100% analyst buy ratings supporting long-term growth potential. However, persistent cash burn, regulatory dependencies on partner therapies like AMT-130, and execution risks present substantial challenges. Investors face high volatility given the speculative nature of its growth trajectory against current profitability concerns.
Trailing returns across standard periods
Latest headlines on both assets
Amazon.com, Inc. is an online retailer that offers a wide range of products. The Company products include books, music, computers, electronics and numerous other products. Amazon offers personalized shopping services, Web-based credit card payment, and direct shipping to customers. Amazon also operates a cloud platform offering services globally.
Read more on AMZN →ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →